Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report)'s stock price gapped down prior to trading on Friday . The stock had previously closed at $16.60, but opened at $16.01. Bicara Therapeutics shares last traded at $16.27, with a volume of 5,771 shares traded.
Wall Street Analyst Weigh In
BCAX has been the subject of a number of recent research reports. HC Wainwright began coverage on shares of Bicara Therapeutics in a research report on Friday, December 6th. They set a "buy" rating and a $42.00 price target for the company. Stifel Nicolaus began coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They set a "buy" rating and a $47.00 target price for the company. Morgan Stanley began coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They issued an "overweight" rating and a $35.00 price target on the stock. RODMAN&RENSHAW raised Bicara Therapeutics to a "strong-buy" rating in a research report on Tuesday, November 5th. Finally, Cantor Fitzgerald assumed coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They set an "overweight" rating for the company. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $43.00.
View Our Latest Stock Report on BCAX
Bicara Therapeutics Trading Up 6.0 %
The company's fifty day moving average is $20.85.
Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($0.46) by ($1.14). As a group, analysts expect that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Bicara Therapeutics
A number of hedge funds have recently bought and sold shares of the business. Cinctive Capital Management LP purchased a new stake in Bicara Therapeutics during the 3rd quarter valued at $229,000. Barclays PLC purchased a new stake in Bicara Therapeutics during the third quarter valued at $255,000. Jane Street Group LLC bought a new position in Bicara Therapeutics in the third quarter valued at about $309,000. Teachers Retirement System of The State of Kentucky purchased a new position in Bicara Therapeutics in the third quarter worth about $358,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Bicara Therapeutics during the 3rd quarter valued at about $462,000.
Bicara Therapeutics Company Profile
(
Get Free Report)
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
Further Reading
Before you consider Bicara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.
While Bicara Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
